ONCT News and Press, Oncternal Therapeutics Inc. From 07/29/21

SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report second quarter 2021 financial results after the U.S. fin...

Oncternal Therapeutics (ONCT) announces the appointment of Pablo Urbaneja as Senior Vice President, Corporate Development.Urbaneja will be responsible for strategic planning and advancing corporate and business development initiatives at Oncternal.Most recently he served as Vic...

SAN DIEGO, July 01, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the appointment of Pablo Urbaneja as Senior Vice President, Corporate Development. ...

Oncternal is a small biotech player with two major assets: Cirmtuzumab and TK216. Recent data updates have solidified Oncternal's approach in Mantle Cell Lymphoma and Ewing Sarcoma. Relatively solid cash balance provides a runway into 2023, with potential methods of avoiding furth...

ONCT presented solid data in MCL and ES. There's potential for accelerated approval. The company has a history of diluting shares. For further details see: Oncternal: Solid Data In 2 Cancers With High Unmet Need

ASCO is a very important cancer clinical research meeting. We identified 70 smid-cap cancer companies presenting updated clinical data at ASCO21. 13 companies' value increased by over 10% with ASCO21 info release thus far. PDSB is an early ASCO21 mover, with its HPV vaccine ca...

SAN DIEGO, June 01, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has granted an inducement award to one new employee, Christopher Markey, who j...

SAN DIEGO, May 26, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that management will present a corporate overview at the Jefferies Virtual Healthcare Confere...

Oncternal Therapeutics (ONCT) added ~9.3% in the premarket after the company disclosed updated interim results from a Phase 1/2 clinical trial evaluating TK216 in patients with relapsed or refractory Ewing sarcoma.The data is contained in an abstract that will be part of a...

Virgin Galactic Holdings (SPCE) +21% after test flight scheduled for May 22VistaGen Therapeutics (VTGN) +15% after Baird calls stock 'significantly undervalued'.Allogene Therapeutics (ALLO) +13% on positive early-stage data for CAR T candidates in blood cancer.PDS Biotechnology...